Promising early data for KITE-753 and azer-cel with IL-2 in R/R LBCL
Prof. Emmanuel Bachy discusses the latest findings for the autologous, rapid manufactured KITE-753 and allogeneic azer-cel in combination with interleukin-2.
Rapcabtagene autoleucel my be a viable frontline option in high-risk LBCL
Dr Jason Westin shares the latest findings on rapcabtagene autoleucel for the treatment of patients with high-risk large B-cell lymphoma autologous in the first-line setting.
Rapcabtagene autoleucel shows frontline promise for high-risk LBCL
Early findings show rapcabtagene autoleucel could be a first-line treatment for patients with high-risk LBCL.
Bispecific, fresh formula CAR-T superior to R-GEMOx in LBCL
Zamto-cel shows survival benefits over R-GEMOx in patients with R/R LBCL who are ineligible for transplant.
Consistent high response with the bispecific prizlo-cel in R/R LBCL
Prizlo-cel maintains high complete response rates in patients with R/R LBCL in a study looking at the potential effects of correlated biomarkers.
Synergistic CAR-T targeting with rapid manufacturing shows LBCL benefits
Support for further development of KITE-753 for relapsed/refractory large B-cell lymphoma after findings suggest a rapid and strong response.
Rapid manufacturing: Speeding up access to effective CAR-T cell therapies
CAR-T-cell therapy has revolutionized the treatment landscape for lymphoma, yet access to this treatment remains constrained by complex and lengthy manufacturing processes.
Latest findings from the ATALANTA-1 trial of GLPG5101
Dr Pim Mutsaers discusses the latest findings from the ATALANTA-1 trial of GLPG5101, which uses a decentralized platform, in patients with R/R NHL.
CAR-T cell therapy in LBCL and immunotherapy highlights
Dr Eddie Cliff sets the scene for CAR-T cell therapy in LBCL and gives some of his immunotherapy highlights from the EHA2025 Congress in Milan, Italy.
Bi-specific CAR-T cell therapy shows promise for R/R LBCL
Early support for further development of dual CD19 and CD20 targeting in CAR-T cell treatment for patients with relapsed/refractory large-B cell lymphoma.
